GEN Exclusives

More »

GEN News Highlights

More »
Oct 23, 2007

Asuragen to Develop Cancer Pharmacogenomic Assay for Merck

  • Asuragen through its pharmacogenomic services division entered into a research collaboration with Merck & Co. to develop a biomarker and diagnostic test for cancer drug development.

    Merck’s oncology research program will identify an expression signature, which Asuragen will use to develop a diagnostic assay. Merck will be able to utilize the test in its cancer clinical trials. The assay may also serve as the basis for commercial companion diagnostic tests for oncology therapies.

    Asuragen will receive upfront fees and expects to complete development in 2008. Upon completion and validation, the company will be eligible to additional payments associated with successful transfer of the diagnostic assays to clinical reference laboratories.

    “Asuragen’s business model of providing GLP molecular biology services, CLIA testing capabilities, and GMP diagnostic assay development and manufacture is uniquely suited to collaborate with pharmaceutical partners in the clinical validation of drugs in development and the potential future companion diagnostic tests,” according to Matt Winkler, Ph.D., CEO and CSO of Asuragen.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »